Emerging evidence is demonstrating the extent of T-cell infiltration within the tumor microenvironment has favorable prognostic and therapeutic implications. Hence, immunotherapeutic strategies that augment the T-cell signature of tumors hold promising therapeutic potential. Recently, immunotherapy based on intratumoral injection of mannan-BAM, toll-like receptor ligands and anti-CD40 antibody (MBTA) demonstrated promising potential to modulate the immune phenotype of injected tumors. The strategy promotes the phagocytosis of tumor cells to facilitate the recognition of tumor antigens and induce a tumor-specific adaptive immune response. Using a syngeneic colon carcinoma model, we demonstrate MBTA's potential to augment CD8+ T-cell tumor infiltrate when administered intratumorally or subcutaneously as part of a whole tumor cell vaccine. Both immunotherapeutic strategies proved effective at controlling tumor growth, prolonged survival and induced immunological memory against the parental cell line. Collectively, our investigation demonstrates MBTA's potential to trigger a potent anti-tumor immune response.

David Geffen School of Medicine University of California Los Angeles California United States

Department of Medical Biology Faculty of Science University of South Bohemia České Budějovice Czech Republic

Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda Maryland United States

Neuro Oncology Branch National Cancer Institute National Institutes of Health Bethesda Maryland United States

Surgical Neurology Branch National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda Maryland United States

UT Health Austin Pediatric Neurosciences at Dell Children's Austin Texas United States

Zobrazit více v PubMed

Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi:10.1038/ni.2703 PubMed DOI PMC

Chen DS, Mellman I. Elements of cancer immunity and the cancer–immune set point. Nature. 2017;541(7637):321–330. doi:10.1038/nature21349 PubMed DOI

Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218. doi:10.1038/s41573-018-0007-y PubMed DOI

Galon J, Angell HK, Bedognetti D, Marincola FM. The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity. 2013;39(1):11–26. doi:10.1016/j.immuni.2013.07.008 PubMed DOI

Fridman WH, Zitvogel L, Sautès-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–734. doi:10.1038/nrclinonc.2017.101 PubMed DOI

Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F. Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. Front Immunol. 2018;9(JAN):14. doi:10.3389/fimmu.2018.00014 PubMed DOI PMC

Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (80- ). 2006;313(5795):1960–1964. doi:10.1126/science.1129139 PubMed DOI

Caisova V, Li L, Gupta G, et al. The Significant Reduction or Complete Eradication of Subcutaneous and Metastatic Lesions in a Pheochromocytoma Mouse Model after Immunotherapy Using Mannan-BAM, TLR Ligands, and Anti-CD40. Cancers (Basel). 2019;11(5):654. doi:10.3390/cancers11050654 PubMed DOI PMC

Caisová V, Uher O, Nedbalová P, et al. Effective cancer immunotherapy based on combination of TLR agonists with stimulation of phagocytosis. Int Immunopharmacol. 2018;59:86–96. doi:10.1016/J.INTIMP.2018.03.038 PubMed DOI

Kato K, Itoh C, Yasukouchi T, Nagamune T. Rapid Protein Anchoring into the Membranes of Mammalian Cells Using Oleyl Chain and Poly(ethylene glycol) Derivatives. Biotechnol Prog. 2004;20(3):897–904. doi:10.1021/bp0342093 PubMed DOI

Janotová T, Jalovecká M, Auerová M, et al. The use of anchored agonists of phagocytic receptors for cancer immunotherapy: B16-F10 murine melanoma model. Gabriele L, ed. PLoS One. 2014;9(1):e85222. doi:10.1371/journal.pone.0085222 PubMed DOI PMC

Figueiredo RT, Carneiro LAM, Bozza MT. Fungal surface and innate immune recognition of filamentous fungi. Front Microbiol. 2011;2:248. doi:10.3389/fmicb.2011.00248 PubMed DOI PMC

Hassan SB, Sørensen JF, Olsen BN, Pedersen AE. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol. 2014;36(2):96–104. doi:10.3109/08923973.2014.890626 PubMed DOI

Caisová V, Vieru A, Kumžáková Z, et al. Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model. BMC Cancer. 2016;16(1):940. doi:10.1186/s12885-016-2982-x PubMed DOI PMC

Urban-Wojciuk Z, Khan MM, Oyler BL, et al. The role of tlrs in anti-cancer immunity and tumor rejection. Front Immunol. 2019;10(OCT):2388. doi:10.3389/fimmu.2019.02388 PubMed DOI PMC

Seo HS, Michalek SM, Nahm MH. Lipoteichoic acid is important in innate immune responses to gram-positive bacteria. Infect Immun. 2008;76(1):206–213. doi:10.1128/IAI.01140-07 PubMed DOI PMC

Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine. 2011;29(17):3341–3355. doi:10.1016/j.vaccine.2010.08.002 PubMed DOI PMC

Bianchi F, Pretto S, Tagliabue E, Balsari A, Sfondrini L. Exploiting poly(I:C) to induce cancer cell apoptosis. Cancer Biol Ther. 2017;18(10):747–756. doi:10.1080/15384047.2017.1373220 PubMed DOI PMC

Rook AH, Gelfand JC, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood. 2015;126(12):1452–1461. doi:10.1182/blood-2015-02-630335 PubMed DOI PMC

WU J, HUANG D, TYRING S. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Res. 2004;64(2):79–83. doi:10.1016/j.antiviral.2004.07.002 PubMed DOI

Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19(5):1035–1043. doi:10.1158/1078-0432.CCR-12-2064 PubMed DOI PMC

Moreau M, Yasmin-Karim S, Kunjachan S, et al. Priming the abscopal effect using multifunctional smart radiotherapy biomaterials loaded with immunoadjuvants. Front Oncol. 2018;8(MAR). doi:10.3389/fonc.2018.00056 PubMed DOI PMC

Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJM. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17(8):2270–2280. doi:10.1158/1078-0432.CCR-10-2888 PubMed DOI

Hunn MK, Farrand KJ, Broadley KWR, et al. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma. Clin Cancer Res. 2012;18(23):6446–6459. doi:10.1158/1078-0432.CCR-12-0704 PubMed DOI

Curry WT, Gorrepati R, Piesche M, et al. Cancer Therapy: Clinical Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. 2016. doi:10.1158/1078-0432.CCR-15-2163 PubMed DOI PMC

Tian H, Shi G, Yang G, et al. Cellular immunotherapy using irradiated lung cancer cell vaccine co-expressing GM-CSF and IL-18 can induce significant antitumor effects. BMC Cancer. 2014;14(1):48. doi:10.1186/1471-2407-14-48 PubMed DOI PMC

Koster BD, Santegoets SJAM, Harting J, et al. Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial. Cancer Immunol Immunother. 2019;68(6):1025–1035. doi:10.1007/s00262-019-02320-0 PubMed DOI PMC

Uyl-de Groot CA, Vermorken JB, Hanna MG, et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine. 2005;23(17–18):2379–2387. doi:10.1016/J.VACCINE.2005.01.015 PubMed DOI

Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefits. J Clin Oncol. 2004;22(21):4272–4281. doi:10.1200/JCO.2004.09.038 PubMed DOI

Van Dalen FJ, Van Stevendaal MHME, Fennemann, Verdoes M, Ilina O. Molecular repolarisation of tumour-associated macrophages. Molecules. 2019;24(1). doi:10.3390/molecules24010009 PubMed DOI PMC

Huang AYC, Guldent PH, Woods AS, et al. The Immunodominant Major Histocompatibility Complex Class I-Restricted Antigen of a Murine Colon Tumor Derives from an Endogenous Retroviral Gene Product (Murine Tumor Antigens/Cytotoxic T Lymphocytes/Endogenous Murine Leukemia Virus/Tandem Mass Spectrome. Vol 93.; 1996. PubMed PMC

Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. T cell responses: Naïve to memory and everything in between. Am J Physiol - Adv Physiol Educ. 2013;37(4):273–283. doi:10.1152/advan.00066.2013 PubMed DOI PMC

Bonaventura P, Shekarian T, Alcazer V, et al. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front Immunol. 2019;10:168. doi:10.3389/fimmu.2019.00168 PubMed DOI PMC

Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):165. doi:10.1038/s12276-018-0191-1 PubMed DOI PMC

Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275. doi:10.1038/NRC.2016.36 PubMed DOI PMC

Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361–375. doi:10.1038/s41575-019-0126-x PubMed DOI PMC

Moynihan KD, Irvine DJ. Roles for innate immunity in combination immunotherapies. Cancer Res. 2017;77(19):5215–5221. doi:10.1158/0008-5472.CAN-17-1340 PubMed DOI PMC

Ahonen CL, Engle X, Martinez DG, et al. In situ Stimulation of CD40 and Toll-like Receptor 3 Transforms Ovarian Cancer-Infiltrating Dendritic Cells from Immunosuppressive to Immunostimulatory Cells. Cancer Res. 2009;69(18):7329–7337. doi:10.1158/0008-5472.can-09-0835 PubMed DOI PMC

Bandola-Simon J, Roche PA. Dysfunction of antigen processing and presentation by dendritic cells in cancer. Mol Immunol. April 2018. doi:10.1016/J.MOLIMM.2018.03.025 PubMed DOI PMC

Zitvogel L, Kepp O, Kroemer G. Decoding Cell Death Signals in Inflammation and Immunity. Cell. 2010;140(6):798–804. doi:10.1016/j.cell.2010.02.015 PubMed DOI

Scheffer SR, Nave H, Korangy F, et al. Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer. 2003;103(2):205–211. doi:10.1002/ijc.10777 PubMed DOI

Torosantucci A, Bromuro C, Chiani P, et al. A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med. 2005;202(5):597–606. doi:10.1084/jem.20050749 PubMed DOI PMC

Toda M, Iizuka Y, Kawase T, Uyemura K, Kawakami Y. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Cancer Gene Ther. 2002;9(4):356–364. doi:10.1038/sj.cgt.7700446 PubMed DOI

Unsworth A, Anderson R, Haynes N, Britt K. OMIP-032 : Two Multi-Color Immunophenotyping Panels for Assessing the Innate and Adaptive Immune Cells in the Mouse Mammary Gland. 2016:527–530. doi:10.1002/cyto.a.22867 PubMed DOI

Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model

rWTC-MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells

Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer

rWTC-MBTA: autologous vaccine prevents metastases via antitumor immune responses

Intratumoral immunotherapy of murine pheochromocytoma shows no age-dependent differences in its efficacy

Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations

Identification of Immune Cell Infiltration in Murine Pheochromocytoma during Combined Mannan-BAM, TLR Ligand, and Anti-CD40 Antibody-Based Immunotherapy

Mannan-BAM, TLR Ligands, Anti-CD40 Antibody (MBTA) Vaccine Immunotherapy: A Review of Current Evidence and Applications in Glioblastoma